{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T20:14:52Z","timestamp":1783714492026,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clbc.2025.12.011","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T16:28:20Z","timestamp":1768235300000},"page":"27-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Event-Free Survival After Stereotactic Body Radiation Therapy for Oligoprogressive Metastatic Breast Cancer"],"prefix":"10.1016","volume":"26","author":[{"given":"Riccardo Ray","family":"Colciago","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5544-8015","authenticated-orcid":false,"given":"Carlotta","family":"Giandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cavallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Carnevale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fotia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Mazzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia Valeria","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena Di","family":"Cosimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Presti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Lobefaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Lozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carmen","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clbc.2025.12.011_bib0001","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.011_bib0002","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for research and treatment of cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.011_bib0003","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijrobp.2024.08.031","article-title":"Stereotactic ablative radiation for oligoprogressive cancers: results of the randomized phase 2 STOP trial","volume":"121","author":"Schellenberg","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.clbc.2025.12.011_bib0004","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ijrobp.2024.09.002","article-title":"The role of stereotactic body radiotherapy in oligoprogressive malignant disease (RADIANT): oncologic outcomes from a phase 2 nonrandomized controlled trial","volume":"121","author":"Glicksman","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clbc.2025.12.011_bib0005","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"Tsai","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2025.12.011_bib0006","article-title":"Stereotactic ablative body radiotherapy for oligoprogressive estrogen receptor\u2013positive breast cancer (TROG 20.03 AVATAR): a phase II prospective multicenter trial","volume":"2","author":"David","year":"2025"},{"issue":"2","key":"10.1016\/j.clbc.2025.12.011_bib0007","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.clbc.2025.12.011_bib0008","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1148\/radiol.2016142043","article-title":"Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0","volume":"280","author":"JH","year":"2016","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.clbc.2025.12.011_bib0009","doi-asserted-by":"crossref","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","article-title":"NCCN Guidelines\u00ae insights: breast Cancer, version 4.2023","volume":"21","author":"Gradishar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"10.1016\/j.clbc.2025.12.011_bib0010","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.clbc.2025.12.011_bib0011","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clbc.2025.12.011_bib0012","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10585-022-10167-6","article-title":"Stereotactic body radiotherapy (SBRT) and concomitant systemic therapy in oligoprogressive breast cancer patients","volume":"39","author":"Nicosia","year":"2022","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.clbc.2025.12.011_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103839","article-title":"Treatment of oligometastatic breast cancer: the role of patient selection","volume":"79","author":"Colciago","year":"2025","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.011_bib0014","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijrobp.2018.12.049","article-title":"Predictive factors for response and survival in a cohort of oligometastatic patients treated with stereotactic body radiation therapy","volume":"104","author":"Franceschini","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"17","key":"10.1016\/j.clbc.2025.12.011_bib0015","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1002\/cncr.25997","article-title":"Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis","volume":"117","author":"Chang","year":"2011","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.clbc.2025.12.011_bib0016","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/jso.25361","article-title":"Outcomes after hypofractionated stereotactic radiotherapy for colorectal cancer oligometastases","volume":"119","author":"Yu","year":"2019","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.clbc.2025.12.011_bib0017","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2021.10.023","article-title":"A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: the LaIT-SABR study","volume":"166","author":"Nicosia","year":"2022","journal-title":"Radiother Oncol"},{"issue":"18","key":"10.1016\/j.clbc.2025.12.011_bib0018","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.clbc.2025.12.011_bib0019","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.011_bib0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.clbc.2025.12.011_bib0021","doi-asserted-by":"crossref","first-page":"6840","DOI":"10.3390\/curroncol31110505","article-title":"Time to next treatment following sub-ablative progression directed radiation therapy for oligoprogressive non-small-cell lung cancer","volume":"31","author":"Colciago","year":"2024","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.011_bib0022","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13014-018-1040-z","article-title":"The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies","volume":"13","author":"Van Leeuwen","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clbc.2025.12.011_bib0023","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2020.01.016","article-title":"Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016","volume":"129","author":"Deluche","year":"2020","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.clbc.2025.12.011_bib0024","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.clbc.2020.05.006","article-title":"Liver metastases-directed therapy in the management of oligometastatic breast cancer","volume":"20","author":"Franzese","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2025.12.011_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115164","article-title":"Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer","volume":"215","author":"Milano","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2025.12.011_bib0026","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.breast.2015.12.002","article-title":"Stereotactic body radiation therapy: a promising chance for oligometastatic breast cancer","volume":"26","author":"Scorsetti","year":"2016","journal-title":"Breast"},{"issue":"3","key":"10.1016\/j.clbc.2025.12.011_bib0027","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10549-008-0157-4","article-title":"Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy","volume":"115","author":"Milano","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2025.12.011_bib0028","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3389\/fonc.2020.00987","article-title":"Extracranial stereotactic body radiotherapy in oligometastatic or oligoprogressive breast cancer","volume":"10","author":"Weykamp","year":"2020","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.clbc.2025.12.011_bib0029","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12032-022-01788-8","article-title":"A critical review on oligometastatic disease: a radiation oncologist's perspective","volume":"39","author":"Pacifico","year":"2022","journal-title":"Med Oncol"},{"key":"10.1016\/j.clbc.2025.12.011_bib0030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/CCI.20.00125","article-title":"Comparisons of real-world time-to-event end points in oncology research","volume":"5","author":"Walker","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.clbc.2025.12.011_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103435","article-title":"Osimertinib plus consolidative radiotherapy for advanced EGFR mutant non-small cell lung cancer: a multicentre, single-arm, phase 2 trial","volume":"87","author":"Sampath","year":"2025","journal-title":"EClinicalMedicine"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682092500357X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682092500357X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:35:50Z","timestamp":1773405350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152682092500357X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S152682092500357X"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2025.12.011","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Event-Free Survival After Stereotactic Body Radiation Therapy for Oligoprogressive Metastatic Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2025.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}